References
Guerrini, M. et al. Nat. Biotechnol. 26, 669–675 (2008).
Trehy, M.L., Reepmeyer, J.C., Kolinski, R.E., Westenberger, B.J. & Buhse, L.F. J. Pharm. Biomed. Anal. 49, 670–673 (2009).
Viskov, C. et al. Clin. Appl. Thromb. Hemost. 15, 395–401 (2009).
McEwen, I. et al. J. Pharm. Biomed. Anal. 49, 816–819 (2009).
Maruyama, T., Toida, T., Imanari, T., Yu, G. & Linhardt, R.J. Carbohydr. Res. 306, 35–43 (1998).
Zhang, Z. et al. J. Pharm. Sci. (in the press).
Guerrini, M. et al. Thromb. Haemost. 102, 907–911 (2009).
Toida, T. et al. Int. J. Biol. Macromol. 26, 233–241 (1999).
Guerrini, M. et al. Proc. Natl. Acad. Sci. USA 106, 16956–16961 (2009).
Casu, B. et al. Carbohydr. Res. 263, 271–284 (1994).
Li, B. et al. Biochem. Pharmacol. 78, 292–300 (2009).
Griffin, C.C. et al. Carbohydr. Res. 276, 183–197 (1995).
Guerrini, M., Naggi, A., Guglieri, S., Santarsiero, R. & Torri, G. Anal. Biochem. 337, 35–47 (2005).
Yates, E.A. et al. Carbohydr. Res. 294, 15–27 (1996).
Toida, T. et al. Biochem. J. 322 (Pt 2), 499–506 (1997).
Bisio, A. et al. Thromb. Haemost. 102, 865–873 (2009).
Kishimoto, T.K. et al. N. Engl. J. Med. 358, 2457–2467 (2008).
Linhardt, R.J. et al. Biochem. Pharmacol. 42, 1609–1619 (1991).
Sudo, M. et al. Anal. Biochem. 297, 42–51 (2001).
Neville, G.A., Mori, F., Holme, K.R. & Perlin, A.S. J. Pharm. Sci. 78, 101–104 (1989).
Yates, E.A. et al. Carbohydr. Res. 329, 239–247 (2000).
Acknowledgements
The authors thank G. Cassinelli, M. Nasr and L. Buhse for discussions and the US National Institutes of Health for grant HL101721 to R.S. and R.J.L. to support this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.S. is a director of Momenta Pharmaceuticals, Z.S. reports receiving consulting fees from Momenta Pharmaceuticals and R.J.L. is a paid consultant for Baxter Pharmaceuticals.
Supplementary information
Supplementary Figures and Tables
Supplementary Figs. 1–3 and Supplementary Table 1 (PDF 1078 kb)
Rights and permissions
About this article
Cite this article
Pan, J., Qian, Y., Zhou, X. et al. Reply to Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol 28, 207–211 (2010). https://doi.org/10.1038/nbt0310-207
Issue Date:
DOI: https://doi.org/10.1038/nbt0310-207
- Springer Nature America, Inc.
This article is cited by
-
Professor Casu’s contribution to cyclodextrins, the remarkable cage-shaped molecules: a review
Environmental Chemistry Letters (2022)
-
Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins
Analytical and Bioanalytical Chemistry (2011)
-
Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples
Analytical and Bioanalytical Chemistry (2011)
-
Analysis and characterization of heparin impurities
Analytical and Bioanalytical Chemistry (2011)